Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on May 31, 2024, the company granted equity awards to four new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
波士顿，2024 年 5 月 31 日（环球新闻专线）-- Verve Therape是一家处于临床阶段的生物技术公司，开创了使用单疗程基因编辑药物治疗心血管疾病的新方法。该公司今天宣布，根据公司2024年的激励股票激励计划，公司于2024年5月31日向四名新员工发放了股权奖励，作为根据纳斯达克上市规则5635（c）（4）在公司工作的每位新员工的激励材料。
The employees received an aggregate of 23,600 restricted stock units (RSUs). The RSUs will vest in equal annual installments on the first four anniversaries of July 1, 2024, subject to each such employee's continued service with the company on each such vesting date.
员工共获得23,600个限制性股票单位（RSU）。RSU将在2024年7月1日的前四个周年纪念日按年等额分期付款，前提是每位此类员工在每个此类归属日期继续在公司任职。
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company's lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally-tolerated standard of care therapies. For more information, please visit www.VerveTx.com.
关于 Verve Therapeu
Verve Therapeutics, Inc.（纳斯达克股票代码：VERV）是一家临床阶段的基因药物公司，开创了一种新的心血管疾病护理方法，有可能将治疗从慢性治疗转变为单疗程基因编辑药物。该公司的主要项目 — VERVE-101、VERVE-102 和 VERVE-201 — 靶向的基因已被广泛验证为降低低密度脂蛋白胆固醇 (LDL-C) 的靶标，低密度脂蛋白胆固醇是动脉粥样硬化性心血管疾病 (ASCVD) 的根本原因。VERVE-101 和 VERVE-102 旨在永久关闭 PCSK9 肝脏中的基因，最初是针对杂合子家族性高胆固醇血症（HeFH）而开发的，最终用于治疗仍受高低密度脂蛋白-C水平影响的已确立ASCVD的患者。VERVE-201 旨在永久关闭 ANGPTL3 肝脏中的基因，最初是针对纯合子家族性高胆固醇血症（HoFH）和难治性高胆固醇血症开发的，在这些情况下，尽管使用最大耐受性标准的护理疗法进行治疗，但患者的低密度脂蛋白水平仍然很高。欲了解更多信息，请访问 www.vervetx.com。
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
投资者联系人
詹·罗宾逊
Verve Thareutics, Inc
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
媒体联系人
Ashlea Kosikowski
1AB
ashlea@1abmedia.com